Citizens Reiterates Buy Rating for Intellia Therapeutics
Citizens maintains a bullish outlook on Intellia Therapeutics with a $30 target.
Key Points
- On June 15, 2026, Citizens reiterated its buy rating for Intellia Therapeutics, setting a $30 price target.
- Intellia Therapeutics trades at $12.11, with a market cap of approximately $1.69 billion and a 52-week high of $28.25.
- Insider purchases were reported on June 9, 2026, with several insiders acquiring shares without a disclosed price.
On June 15, 2026, Citizens reiterated its buy rating for Intellia Therapeutics, Inc. (NasdaqGM: NTLA), maintaining a price target of $30. This decision comes as the stock trades at around $12.11.
Other Institutional Activity in Intellia Therapeutics
ARK Investment Management LLC increased its holdings by 301,923 shares, ending with 14,509,247 shares valued at about $186 million. BlackRock, Inc. boosted its position by 1,878,957 shares, now holding 12,155,806 shares worth roughly $155.8 million. State Street Corp added 503,840 shares, bringing its total to 6,922,676 shares valued at approximately $88.7 million. D. E. Shaw & Co., Inc. also increased its stake by 397,113 shares, totaling 5,728,177 shares with a value of $73.4 million.
Intellia Therapeutics Stock Snapshot
Shares of NasdaqGM:NTLA are trading near $12.11. Intellia Therapeutics has a market cap of about $1.69 billion. The stock has a 52-week low of $7.95 and a high of $28.25. It has a 50-day moving average of $13.63 and a 200-day moving average of $13.39. The company shows a forward P/E ratio that is not meaningful because it is not profitable, with a beta of 1.815.
Recent Earnings
Intellia Therapeutics reported revenue of $66.1 million, reflecting a decline of 9.5%. The company has a net margin of 0% and a return on equity of -56.34%. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at Intellia Therapeutics, Inc.
On June 9, 2026, several insiders, including Fred Cohen, William Chase, and Brian Goff, each acquired 13,300 shares. Muna Bhanji and Georgia Keresty also purchased 9,200 and 13,300 shares, respectively. These transactions were not part of planned sales.
Analysts Set New Price Targets
On June 15, 2026, Citizens reiterated a buy rating with a $30 price target. Wedbush also reiterated its hold rating with a $12 target on the same day. Earlier, Bernstein maintained a hold rating with a $17 target on May 13, 2026. The consensus among 19 analysts is a buy recommendation, with an average price target of $26.63.
About Intellia Therapeutics
Intellia Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts. It focuses on developing therapies using CRISPR/Cas9 technology for genome editing. The company is working on treatments for conditions like transthyretin amyloidosis and hereditary angioedema. Intellia collaborates with various partners to advance its therapeutic pipeline.
Bottom Line
Citizens' reiterated buy rating underscores continued interest in Intellia Therapeutics' potential in genome editing technologies. With its current stock price and analyst targets, investors are closely watching its development efforts. As a reminder, analyst ratings are forward-looking and can change as new information becomes available.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.